Clinical Trial Update: Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Mizagliflozin for postprandial glucose and insulin in adults with post-bariatric hypoglycemia; results have been posted following study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-bariatric Hypoglycemia

Drugs mentioned

• Mizagliflozin (Mizagliflozin)

Snippet

Sponsor: Vogenx, Inc. | Conditions: Postbariatric Hypoglycemia | Phase 2 | Status: COMPLETED | Results posted: 2024-06-25